- Home
- FLC vs ACHV Comparison
FLC vs ACHV Comparison
Compare FLC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- ACHV
- Stock Information
- Founded
- FLC 2003
- ACHV N/A
- Country
- FLC United States
- ACHV United States
- Employees
- FLC N/A
- ACHV N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FLC Finance
- ACHV Health Care
- Exchange
- FLC Nasdaq
- ACHV Nasdaq
- Market Cap
- FLC 174.2M
- ACHV 72.5M
- IPO Year
- FLC N/A
- ACHV N/A
- Fundamental
- Price
- FLC $16.99
- ACHV $2.11
- Analyst Decision
- FLC
- ACHV Strong Buy
- Analyst Count
- FLC 0
- ACHV 3
- Target Price
- FLC N/A
- ACHV $14.33
- AVG Volume (30 Days)
- FLC 37.8K
- ACHV 1.1M
- Earning Date
- FLC 01-01-0001
- ACHV 08-12-2025
- Dividend Yield
- FLC 6.64%
- ACHV N/A
- EPS Growth
- FLC N/A
- ACHV N/A
- EPS
- FLC N/A
- ACHV N/A
- Revenue
- FLC N/A
- ACHV N/A
- Revenue This Year
- FLC N/A
- ACHV N/A
- Revenue Next Year
- FLC N/A
- ACHV N/A
- P/E Ratio
- FLC N/A
- ACHV N/A
- Revenue Growth
- FLC N/A
- ACHV N/A
- 52 Week Low
- FLC $12.62
- ACHV $1.84
- 52 Week High
- FLC $15.45
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- FLC 63.95
- ACHV 53.11
- Support Level
- FLC $16.80
- ACHV $3.44
- Resistance Level
- FLC $16.90
- ACHV $3.90
- Average True Range (ATR)
- FLC 0.12
- ACHV 0.28
- MACD
- FLC 0.00
- ACHV -0.01
- Stochastic Oscillator
- FLC 88.89
- ACHV 56.99
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.